Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment. However, the injection did not cause lower rates of brain swelling and bleeding, which are Leqembi’s most concerning side …
Continue reading “Alzheimer’s drug Leqembi exhibits promise as injection”